GOVX · GeoVax Labs, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These factors collectively raise substantial doubt about the Company's ability to continue as a going concern. Management believes that we will be successful in securing the additional capital required to continue the Company's planned operations, but that our plans do not fully alleviate the substantial doubt about the Company's ability to operate as a going concern.”View the 10-Q filed May 14, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-17 | SPENCER JOHN N JR |
Director |
Award↑
|
Stock Option
|
6,000 |
| 2026-06-17 | Sharkey John W. |
VP, Business Development |
Award↑
Filing footnotes — Stock Option (Direct)
Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. |
Stock Option
|
17,600 |
| 2026-06-17 | Kollintzas Dean G |
Director |
Award↑
|
Stock Option
|
6,000 |
| 2026-06-17 | DODD DAVID A |
Director, President, CEO |
Award↑
Filing footnotes — Stock Option (Direct)
Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. |
Stock Option
|
29,300 |
| 2026-06-17 | CHASE RANDAL D |
Director |
Award↑
|
Stock Option
|
6,000 |
| 2026-06-17 | MCNALLY ROBERT T |
Director |
Award↑
|
Stock Option
|
6,000 |
| 2026-06-17 | Morgan Jayne |
Director |
Award↑
|
Stock Option
|
6,000 |
| 2026-06-17 | McKee Kelly T. Jr. |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Direct)
Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. |
Stock Option
|
17,600 |
| 2026-06-17 | NEWMAN MARK J |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Direct)
Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. |
Stock Option
|
17,600 |
| 2026-06-17 | Lemerond Nicole |
Director |
Award↑
|
Stock Option
|
6,000 |
| 2026-06-17 | Reynolds Mark |
CFO |
Award↑
Filing footnotes — Stock Option (Direct)
Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. |
Stock Option
|
17,600 |
| 2025-10-17 | SPENCER JOHN N JR |
Director |
Buy↑
|
Common Stock
|
10,000 |
| 2025-08-07 | McKee Kelly T. Jr. |
Chief Medical Officer |
Buy↑
|
Common Stock
|
1,107 |
| 2025-06-05 | SPENCER JOHN N JR |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
This stock option was granted on January 2, 2025, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan. Such approval occurred on June 5, 2025, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. |
Stock Option
|
10,000 |
| 2025-06-05 | Lemerond Nicole |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
This stock option was granted on January 2, 2025, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan. Such approval occurred on June 5, 2025, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. |
Stock Option
|
10,000 |
| 2025-06-05 | Morgan Jayne |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
This stock option was granted on January 2, 2025, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan. Such approval occurred on June 5, 2025, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. |
Stock Option
|
10,000 |
| 2025-06-05 | Kollintzas Dean G |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
This stock option was granted on January 2, 2025, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan. Such approval occurred on June 5, 2025, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. |
Stock Option
|
10,000 |
| 2025-06-05 | MCNALLY ROBERT T |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
This stock option was granted on January 2, 2025, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan. Such approval occurred on June 5, 2025, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. |
Stock Option
|
10,000 |
| 2025-06-05 | McKee Kelly T. Jr. |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Direct)
This stock option was granted on January 2, 2025, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan. Such approval occurred on June 5, 2025, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. |
Stock Option
|
70,000 |
| 2025-06-05 | NEWMAN MARK J |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Direct)
This stock option was granted on January 2, 2025, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan. Such approval occurred on June 5, 2025, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. |
Stock Option
|
70,000 |
| 2025-06-05 | Sharkey John W. |
VP, Business Development |
Award↑
Filing footnotes — Stock Option (Direct)
This stock option was granted on January 2, 2025, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan. Such approval occurred on June 5, 2025, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. |
Stock Option
|
70,000 |
| 2025-06-05 | Reynolds Mark |
CFO |
Award↑
Filing footnotes — Stock Option (Direct)
This stock option was granted on January 2, 2025, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan. Such approval occurred on June 5, 2025, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. |
Stock Option
|
70,000 |
| 2025-06-05 | CHASE RANDAL D |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
This stock option was granted on January 2, 2025, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan. Such approval occurred on June 5, 2025, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. |
Stock Option
|
10,000 |
| 2025-06-05 | DODD DAVID A |
Director, President, CEO |
Award↑
Filing footnotes — Stock Option (Direct)
This stock option was granted on January 2, 2025, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan. Such approval occurred on June 5, 2025, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. |
Stock Option
|
185,500 |
| 2025-04-10 | Sharkey John W. |
VP, Business Development |
Buy↑
|
Common Stock
|
6,000 |
| 2025-04-10 | SPENCER JOHN N JR |
Director |
Buy↑
|
Common Stock
|
10,000 |
| 2025-04-01 | DODD DAVID A |
Director, President, CEO |
Buy↑
|
Common Stock
|
10,000 |
| 2025-03-31 | Reynolds Mark |
CFO |
Buy↑
|
Common Stock
|
6,800 |
| 2024-08-12 | Sharkey John W. |
VP, Business Development |
Award↑
Filing footnotes — Stock Option (Direct)
Stock option becomes exercisable in three equal annual installments on the first three anniversary dates of the grant. |
Stock Option
|
15,700 |
| 2024-08-12 | Morgan Jayne |
Director |
Award↑
|
Stock Option
|
8,050 |
| 2024-08-12 | SPENCER JOHN N JR |
Director |
Award↑
|
Stock Option
|
8,050 |
| 2024-08-12 | Reynolds Mark |
CFO |
Award↑
Filing footnotes — Stock Option (Direct)
Stock option becomes exercisable in three equal annual installments on the first three anniversary dates of the grant. |
Stock Option
|
15,700 |
| 2024-08-12 | Kollintzas Dean G |
Director |
Award↑
|
Stock Option
|
8,050 |
| 2024-08-12 | McKee Kelly T. Jr. |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Direct)
Stock option becomes exercisable in three equal annual installments on the first three anniversary dates of the grant. |
Stock Option
|
15,700 |
| 2024-08-12 | NEWMAN MARK J |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Direct)
Stock option becomes exercisable in three equal annual installments on the first three anniversary dates of the grant. |
Stock Option
|
15,700 |
| 2024-08-12 | MCNALLY ROBERT T |
Director |
Award↑
|
Stock Option
|
8,050 |
| 2024-08-12 | CHASE RANDAL D |
Director |
Award↑
|
Stock Option
|
8,050 |
| 2024-08-12 | Lemerond Nicole |
Director |
Award↑
|
Stock Option
|
8,050 |
| 2024-08-12 | DODD DAVID A |
Director, President, CEO |
Award↑
Filing footnotes — Stock Option (Direct)
Stock option becomes exercisable in three equal annual installments on the first three anniversary dates of the grant. |
Stock Option
|
35,000 |
| 2024-08-09 | DODD DAVID A |
Director, President, CEO |
Buy↑
|
Common Stock
|
8,000 |
| 2024-02-22 | DODD DAVID A |
Director, President, CEO |
Buy↑
|
Common Stock
|
8,209 |
| 2024-02-21 | DODD DAVID A |
Director, President, CEO |
Buy↑
|
Common Stock
|
520 |
| 2024-02-07 | Reynolds Mark |
CFO |
Buy↑
|
Common Stock
|
2,000 |
| 2023-12-22 | McKee Kelly T. Jr. |
Chief Medical Officer |
Buy↑
|
Common Stock
|
6,944 |
| 2023-09-25 | McKee Kelly T. Jr. |
Chief Medical Officer |
Buy↑
|
Common Stock
|
9,653 |
| 2023-08-25 | DODD DAVID A |
Director, President, CEO |
Buy↑
|
Common Stock
|
35,087 |
| 2023-08-18 | Reynolds Mark |
CFO |
Buy↑
|
Common Stock
|
10,000 |
| 2023-08-01 | SPENCER JOHN N JR |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
This stock option was granted on December 7, 2022, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of an increase in common shares reserved for the company's stock incentive plan. Such approval occurred on August 1, 2023, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. |
Stock Option
|
50,000 |
| 2023-08-01 | McKee Kelly T. Jr. |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Direct)
This stock option was granted on December 7, 2022, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of an increase in common shares reserved for the company's stock incentive plan. Such approval occurred on August 1, 2023, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. Stock option becomes exercisable in three equal annual installments on the first three anniversary dates of the grant. |
Stock Option
|
15,000 |
| 2023-08-01 | Morgan Jayne |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
This stock option was granted on December 7, 2022, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of an increase in common shares reserved for the company's stock incentive plan. Such approval occurred on August 1, 2023, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. |
Stock Option
|
50,000 |